Enzyme and inhibitor screening requires an active ADAM9 construct with product-specific substrate-cleavage data. A metalloprotease-domain construct provides a focused catalytic format, while an active ectodomain construct retains additional extracellular regions. Reported activity should be interpreted according to the substrate and assay conditions used for each product.

A broader ADAM9 ectodomain construct provides wider epitope coverage for antibody screening than an isolated metalloprotease domain. His-tagged proteins allow flexible capture or solution-phase analysis, while biotinylated His/AviTag™ proteins are compatible with streptavidin-based ELISA, SPR, and BLI assays. Cell-based binding should be evaluated separately when membrane-associated target presentation is relevant.

ACROBiosystems provides a comprehensive portfolio of products supporting every stage of BCMA-targeted CAR-T development, including recombinant BCMA proteins, fluorescently labeled proteins, CAR detection reagents, ActiveMax® BCMA magnetic beads, and analytical tools. These solutions enable antibody screening, CAR detection, cell enrichment, functional evaluation, and quality control, providing an integrated platform to accelerate cell therapy research and development.

The native conformation and biological activity of recombinant BCMA proteins directly influence the interaction between CAR molecules and their target antigen. Using recombinant BCMA proteins with native-like structure, high purity, and excellent batch-to-batch consistency helps minimize experimental variability, improve reproducibility, and enhance the reliability of CAR-T screening and characterization studies.

Recombinant BCMA proteins support a broad range of research and analytical applications, including: CAR candidate screening Anti-BCMA antibody discovery CAR expression detection CAR-T cell binding assays Affinity analysis using ELISA, SPR, and BLI Flow cytometry (FACS) Functional and mechanism-of-action studies These applications span the entire workflow from basic research to analytical development and CMC studies.

High-quality recombinant BCMA proteins play a critical role throughout CAR-T development. They are widely used for CAR candidate screening, antibody discovery, cell-binding assays, CAR expression analysis, functional characterization, and potency studies. Recombinant proteins with high biological activity, high purity, and native-like conformation help generate more reliable and reproducible experimental results, ultimately improving the efficiency of CAR-T research.

BCMA-targeted CAR-T cells are genetically engineered to specifically recognize and eliminate BCMA-positive multiple myeloma cells. Following infusion, these engineered T cells expand in vivo, selectively kill tumor cells, and may provide long-term immune surveillance. As a result, BCMA CAR-T therapies have demonstrated impressive overall response rates (ORR) and complete response (CR) rates in patients with relapsed or refractory multiple myeloma.

Current BCMA-targeted therapies can be broadly classified into three major modalities: BCMA-targeted CAR-T cell therapies BCMA-targeted bispecific antibodies (BsAbs) BCMA-targeted antibody-drug conjugates (ADCs) Each approach offers distinct advantages. CAR-T therapies can induce deep and durable responses, bispecific antibodies provide an off-the-shelf treatment option, and ADCs deliver potent cytotoxic agents directly to BCMA-expressing tumor cells.